[FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis]
Standard
[FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis]. / Klatt, Jan; Hartung, H-P; Hohlfeld, R.
in: NERVENARZT, Jahrgang 78, Nr. 10, 10, 2007, S. 1200-1208.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - [FTY720 (Fingolimod) as a new therapeutic option for multiple sclerosis]
AU - Klatt, Jan
AU - Hartung, H-P
AU - Hohlfeld, R
PY - 2007
Y1 - 2007
N2 - All currently available therapeutic options for multiple sclerosis have to be administered parenterally. Several oral substances are currently in the late clinical development stage. One of them, FTY720 (also known as fingolimod) is highlighted in this review. The biological effects of FTY720 are presented as well as animal data and first clinical data from a phase II trial in multiple sclerosis patients. The effects of FTY720 are based on an innovative approach and apparently target several key elements in the pathogenesis of multiple sclerosis. The first clinical data with FTY720 show very promising results, with a relapse reduction of over 50% compared to placebo and an acceptable safety profile. These results currently await confirmation in two international phase III studies which are recruiting patients worldwide.
AB - All currently available therapeutic options for multiple sclerosis have to be administered parenterally. Several oral substances are currently in the late clinical development stage. One of them, FTY720 (also known as fingolimod) is highlighted in this review. The biological effects of FTY720 are presented as well as animal data and first clinical data from a phase II trial in multiple sclerosis patients. The effects of FTY720 are based on an innovative approach and apparently target several key elements in the pathogenesis of multiple sclerosis. The first clinical data with FTY720 show very promising results, with a relapse reduction of over 50% compared to placebo and an acceptable safety profile. These results currently await confirmation in two international phase III studies which are recruiting patients worldwide.
M3 - SCORING: Zeitschriftenaufsatz
VL - 78
SP - 1200
EP - 1208
JO - NERVENARZT
JF - NERVENARZT
SN - 0028-2804
IS - 10
M1 - 10
ER -
